CHEM-X-INFINITY partnered with I-Stem Institute to identify new treatments for monogenic diseases. Chem-X-Infinity will supply compound libraries, library focusing and early hit-optimization.

CHEM-X-INFINITY will attend the 21st International Symposium of Medicinal Chemistry on September 5-9th, 2009, in Brussels, Belgium.

CHEM-X-INFINITY is pleased to announce that it has received the accreditation for the French R&D tax credit for years 2009 to 2012. The system allows French companies to have a tax credit for R&D services outsourced in approved companies.

CHEM-X-INFINITY attended the 5th Drug Design and Lead Discovery Summit on October 14-16th, 2009, in San Diego, CA. The event covered new and common challenges faced during the research phase of the drug discovery process, as well as exciting and pertinent success stories. The conference had a focus on ligand-based drug design strategies that highlight the alternates, value, applicability, efficacy and effectiveness of pharmacophore-based strategies for lead finding and optimization.

CHEM-X-INFINITY is pleased to announce the signature of an agreement with the Structural Biology Laboratory of the Centro de Investigación Príncipe Felipe (CIPF) for the development of new original chemoinformatic models.

Chem-X-Infinity officially received the Réseau Entreprendre 93 price for 2008 the 7th of April, 2008 at the Usine. The 2008 promotion of 11 new companies was supported by Jean-Luc Petithuguenin, founder and CEO of the Paprec and Helios companies.

CHEM-X-INFINITY is pleased to announce the arrival of Bertrand ZEMMOUR as head of Business Development. Bertrand ZEMMOUR will take part in Chem-X-Infinity’s new challenges and new development paths.

Two new arrivals add to Biocitech's success in attracting cutting-edge companies to the Paris life science park.